ResearcherYonsei UniversityActive in the last 2 years
Kyung In Shin
Matched on ORCID iD 0000-0001-9311-8160; OpenAlex author ID A5055810331, A5121556214. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 23
2024: 2 papers · 2025: 1 paper · 2026: 2 papers
Papers 5
- Clinical and prognostic implications of KRT19 expression in pancreatic ductal adenocarcinoma. Last author DOI 10.21037/tcr-2025-1-2629↗
- Bile-derived RNA N6-methyladenosine (m6A) methylation as a novel liquid biopsy biomarker for pancreatic cancer Co-author DOI 10.3389/fonc.2026.1955611↗
- Early prediction of liver metastasis in pancreatic cancer using routine clinical data: an externally validated machine learning model. Co-author DOI 10.1186/s12885-025-15285-4↗
- Long-Term Outcomes of Neoadjuvant Therapy Versus Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/cam4.70363↗
- Survival predictors in patients with pancreatic cancer on liposomal irinotecan plus fluorouracil/leucovorin: a multicenter observational study. Co-author DOI 10.1177/17588359241279688↗
Closest collaborators
The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Kwang Bum Cho · 2 shared papers, 2026 · strength 0.83
- Jung Hyun Jo · 3 shared papers, 2024–2025 · strength 0.56
- Paper Early prediction of liver metastasis in pancreatic cancer using routine clinical data: an externally validated machine … DOI 10.1186/s12885-025-15285-4↗
- Paper Long-Term Outcomes of Neoadjuvant Therapy Versus Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma. DOI 10.1002/cam4.70363↗
- Paper Survival predictors in patients with pancreatic cancer on liposomal irinotecan plus fluorouracil/leucovorin: a multicen… DOI 10.1177/17588359241279688↗
- Hee Seung Lee · 3 shared papers, 2024–2025 · strength 0.56
- Paper Early prediction of liver metastasis in pancreatic cancer using routine clinical data: an externally validated machine … DOI 10.1186/s12885-025-15285-4↗
- Paper Long-Term Outcomes of Neoadjuvant Therapy Versus Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma. DOI 10.1002/cam4.70363↗
- Paper Survival predictors in patients with pancreatic cancer on liposomal irinotecan plus fluorouracil/leucovorin: a multicen… DOI 10.1177/17588359241279688↗
- Moon Jae Chung · 3 shared papers, 2024–2025 · strength 0.56
- Paper Early prediction of liver metastasis in pancreatic cancer using routine clinical data: an externally validated machine … DOI 10.1186/s12885-025-15285-4↗
- Paper Long-Term Outcomes of Neoadjuvant Therapy Versus Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma. DOI 10.1002/cam4.70363↗
- Paper Survival predictors in patients with pancreatic cancer on liposomal irinotecan plus fluorouracil/leucovorin: a multicen… DOI 10.1177/17588359241279688↗
- Jeong Youp Park · 3 shared papers, 2024–2025 · strength 0.56
- Paper Early prediction of liver metastasis in pancreatic cancer using routine clinical data: an externally validated machine … DOI 10.1186/s12885-025-15285-4↗
- Paper Long-Term Outcomes of Neoadjuvant Therapy Versus Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma. DOI 10.1002/cam4.70363↗
- Paper Survival predictors in patients with pancreatic cancer on liposomal irinotecan plus fluorouracil/leucovorin: a multicen… DOI 10.1177/17588359241279688↗
- Seungmin Bang · 3 shared papers, 2024–2025 · strength 0.56
- Paper Early prediction of liver metastasis in pancreatic cancer using routine clinical data: an externally validated machine … DOI 10.1186/s12885-025-15285-4↗
- Paper Long-Term Outcomes of Neoadjuvant Therapy Versus Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma. DOI 10.1002/cam4.70363↗
- Paper Survival predictors in patients with pancreatic cancer on liposomal irinotecan plus fluorouracil/leucovorin: a multicen… DOI 10.1177/17588359241279688↗
- Hyung Jun An · 1 shared paper, 2026 · strength 0.50
- Jiyoung Keum · 2 shared papers, 2024–2025 · strength 0.38
- Paper Early prediction of liver metastasis in pancreatic cancer using routine clinical data: an externally validated machine … DOI 10.1186/s12885-025-15285-4↗
- Paper Survival predictors in patients with pancreatic cancer on liposomal irinotecan plus fluorouracil/leucovorin: a multicen… DOI 10.1177/17588359241279688↗
- Jae Hee Cho · 2 shared papers, 2024–2025 · strength 0.38
- Paper Early prediction of liver metastasis in pancreatic cancer using routine clinical data: an externally validated machine … DOI 10.1186/s12885-025-15285-4↗
- Paper Survival predictors in patients with pancreatic cancer on liposomal irinotecan plus fluorouracil/leucovorin: a multicen… DOI 10.1177/17588359241279688↗
- Sung Ill Jang · 2 shared papers, 2024–2025 · strength 0.38
- Paper Early prediction of liver metastasis in pancreatic cancer using routine clinical data: an externally validated machine … DOI 10.1186/s12885-025-15285-4↗
- Paper Survival predictors in patients with pancreatic cancer on liposomal irinotecan plus fluorouracil/leucovorin: a multicen… DOI 10.1177/17588359241279688↗
- Jee Hoon Kim · 2 shared papers, 2024–2025 · strength 0.38
- Paper Early prediction of liver metastasis in pancreatic cancer using routine clinical data: an externally validated machine … DOI 10.1186/s12885-025-15285-4↗
- Paper Long-Term Outcomes of Neoadjuvant Therapy Versus Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma. DOI 10.1002/cam4.70363↗
- Seung Woo Park · 2 shared papers, 2024 · strength 0.36
- Paper Long-Term Outcomes of Neoadjuvant Therapy Versus Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma. DOI 10.1002/cam4.70363↗
- Paper Survival predictors in patients with pancreatic cancer on liposomal irinotecan plus fluorouracil/leucovorin: a multicen… DOI 10.1177/17588359241279688↗
- Jin-Yi Han¹ · 1 shared paper, 2026 · strength 0.33
- Keun Soo Ahn · 1 shared paper, 2026 · strength 0.33
- Y.J. Ko · 1 shared paper, 2025 · strength 0.20
- Mi‐Suk Park · 1 shared paper, 2024 · strength 0.18
- Seung‐seob Kim · 1 shared paper, 2024 · strength 0.18
- Sang Hoon Lee · 1 shared paper, 2024 · strength 0.18
- Min Sung Yoon · 1 shared paper, 2024 · strength 0.18
- Huapyong Kang · 1 shared paper, 2024 · strength 0.18
- Chan Su Park · 1 shared paper, 2024 · strength 0.18
- Ho Kyoung Hwang · 1 shared paper, 2024 · strength 0.18
- Chang Moo Kang · 1 shared paper, 2024 · strength 0.18
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.